Published online before print January 27, 2005, doi: 10.1161/01.ATV.0000157899.35660.61
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Brief Reviews |
Transcriptional Control of COX-2 via C/EBPß
From the Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, University of Texas Health Science Center at Houston, Tex.
Correspondence to Kenneth K. Wu, Vascular Biology Research Center, Institute of Molecular Medicine and Division of Hematology, University of Texas Health Science Center at Houston, 6431 Fannin, MSB 5.016, Houston, TX 77030. E-mail Kenneth.K.Wu{at}uth.tmc.edu
Cyclooxygenase-2 (COX-2) is a highly inducible enzyme exerting diverse actions on cell functions, including proliferation, migration, and DNA damage. Enhanced COX-2 expression may be protective, but excessive expression may be harmful, causing inflammation, atheromatous plaque instability, and intimal hyperplasia. COX-2 transcriptional activation by proinflammatory mediators has been extensively characterized. In this review, the role of C/EBP in regulating COX-2 transcription is highlighted. Recent advances in control of COX-2 transcription by aspirin and salicylate and by a cell cycle-dependent endogenous mechanism are described. The recent progress sheds light on the pathophysiological mechanisms of COX-2 and new transcription-based strategy for controlling COX-2 overexpression and COX-2–mediated cardiovascular diseases.
Cyclooxygenase-2 (COX-2) is a highly inducible enzyme exerting diverse actions on cell functions, including proliferation, migration, and DNA damage. Enhanced COX-2 expression may be protective, but excessive expression may be harmful, causing inflammation, atheromatous plaque instability, and intimal hyperplasia. In this review, the role of C/EBP in regulating COX-2 transcription is highlighted.
Key Words: aspirin • C/EBP • COX-2 • inflammation • NF-
B
This article has been cited by other articles:
 |
|
 |
|
  J. Liu, E.-S. Park, and M. Jo Runt-Related Transcription Factor 1 Regulates Luteinized Hormone-Induced Prostaglandin-Endoperoxide Synthase 2 Expression in Rat Periovulatory Granulosa Cells Endocrinology, July 1, 2009; 150(7): 3291 - 3300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Staiger, M. J. Lueben, D. Berrigan, R. Malik, S. N. Perkins, S. D. Hursting, and P. F. Johnson C/EBP{beta} regulates body composition, energy balance-related hormones and tumor growth Carcinogenesis, May 1, 2009; 30(5): 832 - 840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Oyesanya, Z. P. Lee, J. Wu, J. Chen, Y. Song, A. Mukherjee, P. Dent, T. Kordula, H. Zhou, and X. Fang Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells FASEB J, August 1, 2008; 22(8): 2639 - 2651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mohan, P. P. Aye, J. T. Borda, X. Alvarez, and A. A. Lackner CCAAT/Enhancer Binding Protein {beta} Is a Major Mediator of Inflammation and Viral Replication in the Gastrointestinal Tract of Simian Immunodeficiency Virus-Infected Rhesus Macaques Am. J. Pathol., July 1, 2008; 173(1): 106 - 118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cortes-Canteli, R. Luna-Medina, M. Sanz-SanCristobal, A. Alvarez-Barrientos, A. Santos, and A. Perez-Castillo CCAAT/enhancer binding protein {beta} deficiency provides cerebral protection following excitotoxic injury J. Cell Sci., April 15, 2008; 121(8): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Taketa, T. Matsumura, M. Yano, N. Ishii, T. Senokuchi, H. Motoshima, Y. Murata, S. Kim-Mitsuyama, T. Kawada, H. Itabe, et al. Oxidized Low Density Lipoprotein Activates Peroxisome Proliferator-activated Receptor-{alpha} (PPAR{alpha}) and PPAR{gamma} through MAPK-dependent COX-2 Expression in Macrophages J. Biol. Chem., April 11, 2008; 283(15): 9852 - 9862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Cruz, J D Quintana-Hau, J R Gonzalez, R Tornero-Montano, L M Baiza-Duran, and L Vega Effects of an ophthalmic formulation of meloxicam on COX-2 expression, PGE2 release, and cytokine expression in a model of acute ocular inflammation Br J Ophthalmol, January 1, 2008; 92(1): 120 - 125. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F.A. Vogel, W. Li, E. Sciullo, J. Newman, B. Hammock, J. R. Reader, J. Tuscano, and F. Matsumura Pathogenesis of Aryl Hydrocarbon Receptor-Mediated Development of Lymphoma Is Associated with Increased Cyclooxygenase-2 Expression Am. J. Pathol., November 1, 2007; 171(5): 1538 - 1548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.-G. Deng, A. J. Montero, and K. K. Wu Interferon-{gamma} Suppresses Cyclooxygenase-2 Promoter Activity by Inhibiting C-Jun and C/EBP{beta} Binding Arterioscler Thromb Vasc Biol, August 1, 2007; 27(8): 1752 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zheng, S. J. Howell, D. A. Hatala, K. Huang, and T. S. Kern Salicylate-Based Anti-Inflammatory Drugs Inhibit the Early Lesion of Diabetic Retinopathy Diabetes, February 1, 2007; 56(2): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rummel, C. Sachot, S. Poole, and G. N. Luheshi Circulating interleukin-6 induces fever through a STAT3-linked activation of COX-2 in the brain Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2006; 291(5): R1316 - R1326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Mukhopadhyay, M. A. Ali, A. Nandi, P. Carreon, H. Choy, and D. Saha The Cyclin-Dependent Kinase 2 Inhibitor Down-regulates Interleukin-1{beta}-Mediated Induction of Cyclooxygenase-2 Expression in Human Lung Carcinoma Cells Cancer Res., February 1, 2006; 66(3): 1758 - 1766. [Abstract] [Full Text] [PDF]
|
|